Syncom Formulations (India) Limited

Total Valuation

Syncom Formulations (India) Limited carries a market capitalization of 13.70B, placing it among publicly traded companies globally. Its enterprise value stands at 11.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Syncom Formulations (India) Limited trades at a trailing price-to-earnings ratio of 17.20.

Enterprise Valuation

On an enterprise value basis, Syncom Formulations (India) Limited trades at an EV/EBITDA multiple of 16.23 and an EV/FCF ratio of 2,107.99. The EV/Sales ratio of 2.40 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.23 provides insight into valuation relative to core operating earnings.

Financial Position

Syncom Formulations (India) Limited maintains a current ratio of 9.24, meaning it holds 9.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.52, indicating elevated leverage, while an interest coverage ratio of 98.71 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Syncom Formulations (India) Limited has paid 217.59M in income taxes, reflecting an effective tax rate of 23.99.

Stock Price Statistics

Syncom Formulations (India) Limited's stock has declined approximately -30.05281% over the past 52 weeks. The 50-day moving average sits at 13.63, while the 200-day moving average is 14.55.

Income Statement

Over the trailing twelve months, Syncom Formulations (India) Limited generated 4.95B in revenue and converted that into 689.58M in net income, yielding earnings per share of 0.83. EBITDA reached 730.44M, while operating income came in at 730.44M.

Margins

Syncom Formulations (India) Limited operates with a gross margin of 37.49, reflecting its pricing power and cost economics. The operating margin of 14.76 and net profit margin of 13.93 provide insight into operational efficiency.

Scores

Syncom Formulations (India) Limited posts an Altman Z-Score of 16.42, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.